The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

The prognostic test stratifies hospitalized women with hypertensive disorders of pregnancy into low- and high-risk categories for developing severe preeclampsia.

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion ... With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics ...

Roche and Eli Lilly have started testing a blood test that could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain scans and speeding up the ...

Roche Holding said the U.S. Food and Drug Administration approved a test to identify patients with a specific type of breast cancer. The Swiss pharmaceutical company said the FDA backed a label ...

1 The Roche Diagnostics Tina-quant® Lipoprotein (a) Gen.2 Molarity assay is an in-vitro test measuring lipoprotein (a) in a person's bloodstream (serum and plasma), and will be broadly available ...

"The HPV test will be rolled out on February 4 to coincide with World Cancer Day," an official with Metropolis said ...

Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...